Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) EBITDA (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed EBITDA for 4 consecutive years, with -$5.9 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 90.02% to -$5.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$160.0 million, a 42.34% increase, with the full-year FY2025 number at -$160.0 million, up 42.34% from a year prior.
  • EBITDA was -$5.9 million for Q4 2025 at Phathom Pharmaceuticals, up from -$15.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$5.9 million in Q4 2025 to a low of -$78.9 million in Q1 2025.
  • A 4-year average of -$48.6 million and a median of -$46.0 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 143.84% in 2024, then surged 90.02% in 2025.
  • Phathom Pharmaceuticals' EBITDA stood at -$46.6 million in 2022, then crashed by 49.81% to -$69.9 million in 2023, then rose by 14.97% to -$59.4 million in 2024, then soared by 90.02% to -$5.9 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's EBITDA are -$5.9 million (Q4 2025), -$15.3 million (Q3 2025), and -$59.9 million (Q2 2025).